INTRODUCTION: Increasing antimicrobial resistance with Helicobacter pylori infection has focused efforts to tailor eradication therapy based on identifying genetic markers of resistance to predict antimicrobial susceptibility. METHODS: In this retrospective study, we report the effect of routine inclusion of antimicrobial susceptibility testing and recommendations for eradication therapy with gastric specimens with H. pylori. RESULTS: The use of a recommended treatment regimen based on genetic markers of resistance was associated with an 84% rate of eradication success and 4.4 greater odds of eradication relative to unrecommended treatment. DISCUSSION: This is the first study describing the use of H. pylori genetic resistance testing as standard of care.

The use of 16S rRNA sequencing in culture-negative infections has improved identification of bacterial pathogens in select scenarios, but its clinical impact requires further elucidation, especially in the pediatric population. This retrospective study aims to determine the clinical utility of 16S rRNA sequencing on the clinical management of pediatric culture-negative infections in our institution. Significant clinical utility was identified in 30 (40.5%) of 74 clinical samples (p < 0.0001). Of all specimens, pulmonary samples yielded the most clinical utility (n = 9, 30%), followed equally by joint fluid (n = 6, 20%) and bone (n = 6, 20%), with no difference between fluid and fresh tissue specimens (p = 0.346). Although the difference was not statistically significant (p = 0.4111), the overall use of broad-spectrum coverage was decreased. The median number of antibiotics was decreased from two to one (p < 0.0001) based on 16S rRNA sequencing results. The results suggest that 16S rRNA sequencing has a significant impact on decreasing the number of antibiotics used in the treatment of pediatric culture-negative infections. 16S rRNA sequencing performed on pulmonary specimens has the highest likelihood of identifying a pathogen compared to other specimen types. Additional cost–benefit analysis needs to be completed to further determine clinical benefit.

Background: The development of broad-range polymerase chain reaction (BR-PCR) and next-generation sequencing techniques has significant implications for antimicrobial stewardship by increasing clinicians’ ability to provide a tailored antimicrobial regimen. We sought to explore the clinical utility of BR-PCR testing and its impact on antimicrobial treatment among an adult cohort in a large hospital system. Methods: We retrospectively evaluated samples that underwent BR-PCR testing between 2017 and 2021 and summarized their clinical characteristics and impact on antimicrobial therapy. We identified BR-PCR testing as having clinical utility if the results led to adjustment of antimicrobial choice or duration or to confirmation of the initial empiric regimen, while no clinical utility was assigned to results that were negative or clinically insignificant, unavailable due to loss to follow-up, or lacking clinical indication (treatment completed before the test results returned or conventional cultures revealed the causative pathogen). Results: Among 359 specimens, BR-PCR was positive for 107 (30%). Clinical utility was identified for 106 (29.5%) specimens, including 45 with negative BR-PCR results. The rates of clinical utility varied based on the type of sample tested, with the highest clinical utility associated with cranial samples (60%), followed by body fluid (56%) and endovascular (54%) samples, and the lowest with CSF (15%) and bone and joint (19%) samples. We also identified many BR-PCR tests that were not clinically indicated (23.4%). Conclusions: This study highlights the utility of BR-PCR testing to support antimicrobial stewardship initiatives. Further studies are needed to identify clinical scenarios in which it is appropriate to order BR-PCR testing and for a careful interpretation of negative BR-PCR results.

Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogen commonly implicated in pneumonia for which vancomycin is often used to cover empirically. Our study examined the impact of a pharmacy-based automatic MRSA polymerase chain reaction (PCR) nares intervention. Methods: We included patients prescribed vancomycin for pneumonia and defined three cohorts: pre-intervention (Cohort 1), post-test implementation (Cohort 2), and post-test implementation with electronic medical record (EMR) enhancements and active stewardship involvement (Cohort 3). The primary outcome was total duration of vancomycin treatment. We performed a desirability of outcome ranking with response adjusted for duration of antibiotic risk (DOOR/RADAR) analysis to prioritize clinical outcomes including adverse events, escalation of care, and death. Results: The median duration of vancomycin therapy decreased between Cohorts 1 and 2 (55 versus 47 hours, p = 0.15), with a greater decrease detected among the subset of Cohort 2 patients from whom the PCR test was actually collected (42 hours, p = 0.035). Duration of therapy was lowest in Cohort 3 (22.3 hours, p < 0.001). In the DOOR/RADAR analysis, no meaningful difference in clinical outcomes was detected between Cohorts 1 and 2 ( p = 0.55). Cohort 3 had substantially better ranked outcomes when compared to Cohorts 1 and 2 ( p < 0.001). Conclusion: Vancomycin treatment duration was shorter in patients after a pharmacy-directed, EMR-based MRSA PCR intervention was implemented, with a greater response after implementation of additional EMR enhancements and active stewardship involvement, improving test collection rate and result response. This study will help inform future interventions pairing automated EMR-based interventions with stewardship team efforts.